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GMZ-gangliosidoses are neurological disorders caused by a genetic deficiency of either thea-hexosaminidase A or the GM2 activator, a glycolipid 
binding protein. In a patient with an immunologically proven GM2 activator protein deficiency, A p’* + C transition (counted from A of the 
initiation codon) was found in the coding sequence, which results in the substitution of Arg for the normal Cys”’ in the mature GM2 activator 
protein. The remainder of the coding sequence remained entirely normal. 
GMZ-gangliosidosis AB variant; GM2 activator protein; Mutation: &Hexosaminidase; Ganglioside; Glycolipid-binding protein 
1, JNTRODLJCTION 
The GM&gangliosidoses are a group of inherited dis- 
orders caused by an accumulation of ganglioside GM2 
and a few related glycolipids mainly in the neurons of 
the patients (for review, see [ 11). The lysosomal degrada- 
tion of ganglioside GM2 requires a catalytically Y&W 
P-hexosaminidase A, which consists of two subunits, oe 
and /-I, and in addition, a hexosaminidase A specific 
glycolipid binding protein, the GM2 activator. 
Inherited defects in any of the three protein eompo- 
nents in the system, /M~exosaminidase subunits 01 and 
a, and the GM2 activator protein, thus may cause a 
GM2-gangliosidosis. Up to now, multiple genetic ab- 
normalities in the a! and /I subunits of the/Lhexosamini- 
dase have been identified. Mutations in the a-chain lead 
to Tay-Sachs disease, while mutations in the p-chain 
are responsible for the failure of both @-hexosaminidase 
A (I@) and 5 @I,,@ in Sandhoff s disease. GMZ-ganglio- 
sidosis due to defective GM2 activator protein but with 
normal jI-hexosaminidase isoenzymes is known as AB 
variant [I 1. 
The information on the complete sequence of the 
cDNA coding for the normal human GM2 activator 
protein and the structural organization of its gene [2,3], 
made it possible to elucidate for the first time the genetic 
cause of the GM2 activator deficiency in a patient with 
GM2 gangliosidosis variant AB. 
Abbreviations: /Lhexosaminidase, B-N-acetyl-D-hexosaminidase, (EC 
3.2.1.52); PCR, polymerase chain reaction 
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2. MATERIALS AND METHODS 
2. I. Patient 
Cultured fibroblasts of a patient with proven GM%gangliosodosis 
AB variant were used for the study [4]. The patient was a black female, 
who died at the age of 14 months. Diagnosis of GMZ-gangliosidosis 
AB variant was established by a pathological accumulation ofganglio- 
side GM2 in brain biopsy tissue, similar to classical Tay-Sachs dis- 
ease, without a deficiency of @-hexosaminidase activities [4], Recent 
immunological studies gave evidence for lack of GM2 activator pro- 
tein in cultured fibroblasts of the patient [S]. 
2.2. RNA isolation and charucterization 
Total RNA was isolated from cultured skin fibroblasts by using the 
guanidine isothiocyanate/cesium chloride procedure [6]. Poly(A) RNA 
was selected using Type 7 oligo(dY) cellulose (Phannacia, Freiburg). 
Northern transfer of electrophoresed mRNA onto nitrocellulose 
membranes was done according to Ausubel et al. [7]. 
2.3. Isolution of genomic DNA 
Genomic DNA was isolated from cultured fibroblasts according to 
a method of Ausubel et al. [7]. 
2.4. PCR Ampl@ution of cDNA and genomic DNA 
First strand cDNA was synthesized from total RNA by specific 
oligonucleotide primers (Fig. I), using the kit purchased from Pro- 
mega (Madison, WI) according to the manufacturer’s instructions. 
The entirc protein coding sequence including 33 bases of the Y-untrans- 
lated region and 96 bases of the 3’-untranslated region was amplified 
by PCR [8], using a series of synthetic I&2l-mer oligonucleotide 
primers (Fig. I). The genomic fragment containing the mutation was 
amplified by PCR based on the known exonjintron structure of the 
gene (Fig. I). 
2.5. Direct sequencing of the DNA 
The amplified DNA was purified by centrifuge-driven dialysis on 
a Centricon 30 microconcentrator (Amicon, Beverley, MA). Direct 
sequencing of the PCR-products was done by employing a Scquenase 
kit (United States Biochemical Co., Cleveland, OH) and the method 
of Wong et al. [9]. A total offive synthetic l8-21.mer oligonuclcotide 
sequencing primers were used (Fig. 1). 
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Fig. 1. Organization of the full length cDNA of the GM2 activator 
protein and location of the PCR and sequencing primers. The primer 
combinations used for amplification are shown above the bars reprc- 
senting the PCR products of cDNA (a) and genomic DNA (b). The 
position of the starting base of the PCR primer is numbered from the 
A of the initiation codon. 
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3. RESULTS AND DISCUSSION 
Fig. 3. The gcnomic sequence (a) of the patient’s GM2 activntol 
protein and (b) of a normal control. The T + C transition is indicated 
by a star. 
Northern blotting experiments on the poly (A) RNA 
fraction showed the presence of the GM2 activator pro- 
tein mRNA ofapparently normal size (data not shown). batches of cDNA, each prepared by amplification of 
cDNA analysis was done by RX-amplification and different batches of cellular RNA (Fig. 2). 
direct-sequencing of the entire protein coding region. Amplification and seq.uencing of the genomic DNA 
No abnormality in the cDNA sequence was found, ex- around the mutation produced the mutated sequence 
cept for a T412 -+ C transition (numbering from the A each time (three times) (Fig. 3). Two assumptions are 
of the initiation codon). which leads to a substitution of possible: first, the patient is homozygous for the identi- 
Arg for Cys’07 in the mature GM2 activator protein. fied mutation and second, one allele has the identified 
This T412 -+ C transition was observed in 4 different mutation and the other allele has a deletion in the areas 
W b) 
of either or both of the primers. In either case, only the 
mutated protein is expressed in the patient’s tissue. 
A G C T A G C T The mutation eliminates the seventh of the eight Cys 
residues in the mature protein and thus can result in a 
failure to form normal disulfide bonds. The resulting 
destabilization of the normal three-dimensional struc- 
ture could prevent the normal processing and transport 
T 
3 
to the lysosome and/or could make! the mutant protein 
sensitive to proteolytic degradation. Either possibilities 
c 
c can explain the lack of GM2 acti.vator protein in the 
T patient’s tissue. 
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